1-Methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one, 98%, 1g

4-Bromobenzyl chloride, 97.0%, 5g

tert-Butyl (2R,3S)-(-)-6-oxo-2,3-diphenyl-4-morpholinecarboxylate, 98.0%, 2.5g

1H-3a,7-Methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-,(3R,3aS,7S,8aS)-, 95%, 5g

4-Fluoro-3-(tetrahydrofuran-3-yl)-1H-indole, 1g

tert-Butyl 7-(3-ethoxy-3-oxopropyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate, 95.0%, 1g

2-Isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole, 97%, 5g

4-Chloro-3,4'-difluorobenzhydrol, 97.0%, 5g

2-Bromo-3-fluoro-6-hydroxybenzaldehyde, 98%, 1g

Oxion Inverso OX.2053-PLPH-ICSI con objetivos LWD Plan fase 10x/20x/40x, equipo ICSI y mesa cruzada XY

Na-Butyloxycarbonyl-L-diaminopropionic acid, 99.0%, 5g

2-Hydroxy-N-phenylacetamide, 95.0%, 1g

2-(Bromomethyl)oxazole hydrobromide, 98%, 100mg